The U.S. Food and Drug Administration is cracking down on drugmakers that refuse to provide samples of brand name products to competitors trying to develop generic alternatives — just one strategy drug companies are using to thwart competition.
A generic-drug developer needs samples of the brand drug to perform what are usually straightforward studies for FDA approval, Commissioner Scott Gottlieb said in a statement last week.
The agency has received more than 150 requests from generic-drug developers for help in obtaining the brand-name samples, he said.
“Without these sam...
Comments